Evotec AG has entered into a research alliance with Panion, Ltd., a subsidiary of Convergence Pharmaceuticals, to discover and develop compounds against a novel GPCR pain target. Evotec will be responsible for key drug discovery activities and will work with Convergence to identify preclinical candidates during a period of three years. If certain preclinical milestones are achieved, Convergence and Evotec will jointly develop the assets into the clinic or via partnering. Financial details were n...